Clinical

Dataset Information

Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.


ABSTRACT: Interventions: We use three drugs (CPT-11, S-1, bevacizumab) for this trial. The treatment schedule of CPT-11 and bevacizumab are administrated on day 1 and day 15, and of S-1 is administrated between day1 and day 21. The dosage of CPT-11 are 75 mg/m2, and of S-1 are 65 mg (the dosage are calculated by body surface area), and of bevacizumab are 10 mg/kg. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2617120 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR